Ambrx Biopharma Net Profit Margin 2020-2021 | AMAM

Ambrx Biopharma net profit margin from 2020 to 2021. Net profit margin can be defined as net Income as a portion of total sales revenue.
Ambrx Biopharma Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.159B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00